Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Meningioma × vistusertib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Stomach Neoplasms 2 Solid Tumor 2 Neoplasms 2 Triple Negative Breast Neoplasms 1 Small Cell Lung Carcinoma 1 Recurrence 1 Prostatic Neoplasms 1 Non-small Cell Lung Cancer Metastatic 1 Meningioma 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Lung Neoplasms 1 Estrogen Receptor Positive Breast Cancer 1 Endometrial Neoplasms 1 Disease 1 Carcinoma, Squamous Cell 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma 1 Breast Neoplasms 1 Advanced Cancer 1 Adenocarcinoma 1

Interventions

Magnetic Resonance Spectroscopy 11 gallium Ga 68 dotatate 6 Everolimus 6 lutetium Lu 177 dotatate 5 Radiosurgery 5 Proton Therapy 5 pembrolizumab 4 Surveys and Questionnaires 4 Specimen Handling 4 Hydroxyurea 4 abemaciclib 3 Tranexamic Acid 3 Surgical Procedures, Operative 3 Ga(III)-DOTATOC 3 Bevacizumab 3 trametinib 2 arginyllysine 2 Yoga 2 Whole Body Imaging 2 Sunitinib 2 Sodium Chloride 2 Radiotherapy 2 Protons 2 Observation 2 Mental Status and Dementia Tests 2 Magnetic Resonance Imaging 2 Imatinib Mesylate 2 Gadolinium DTPA 2 Fluorodeoxyglucose F18 2 Filgrastim 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03071874 2022-10-18

Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas

Massachusetts General Hospital

Phase 2 Unknown

Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡